The anti-lymphoma activities of anti-CD137 monoclonal antibodies are enhanced in FcγRIII-/- mice

Michelle A. Sallin, Xiaoyu Zhang, Edward C. So, Erin Burch, Ling Cai, Wei Lin, Andrei Chapoval, Scott E. Strome

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Agonistic monoclonal antibodies (mAbs) directed against the co-signaling molecule CD137 (4-1BB) elicit potent anti-tumor immunity in mice. This anti-tumor immunity has traditionally been thought to result from the ability of the Fab portion of anti-CD137 to function as an analog for CD137L. Although binding of CD137 by anti-CD137 mAbs has the potential to cross-link the Fc fragments, enabling Fc engagement of low to moderate affinity Fc gamma receptors (FcγR), the relative import of such Fc-FcγR interactions in mediating anti-CD137 associated anti-tumor immunity is unknown. We studied the ability of a rat anti-mouse CD137 mAb (2A) to mediate the anti-tumor response against the EL4E7 lymphoma in WT and FcγR-/- strains. 2A-treated FcRγ-/- mice had improved anti-tumor immunity against EL4E7, which could be completely recapitulated in FcγRIII -/- animals. These improved anti-tumor responses were associated with increased splenic CD8β T cell and dendritic cell (DC) populations. Furthermore, there was an increase in the number of DCs expressing high levels of the CD40, CD80, and CD86 molecules that are associated with more effective antigen presentation. Our results demonstrate an unexpected inhibitory role for FcγRIII in the anti-tumor function of anti-CD137 and underscore the need to consider antibody isotype when engineering therapeutic mAbs.

Original languageEnglish (US)
Pages (from-to)947-958
Number of pages12
JournalCancer Immunology, Immunotherapy
Volume63
Issue number9
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Lymphoma
IgG Receptors
Monoclonal Antibodies
Immunity
Neoplasms
Immunoglobulin Fc Fragments
Antigen Presentation
Dendritic Cells
T-Lymphocytes
Antibodies
Population

Keywords

  • 4-1BB
  • Cancer
  • CD137
  • Dendritic cell
  • Fcγ receptor
  • Monoclonal antibody

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

The anti-lymphoma activities of anti-CD137 monoclonal antibodies are enhanced in FcγRIII-/- mice. / Sallin, Michelle A.; Zhang, Xiaoyu; So, Edward C.; Burch, Erin; Cai, Ling; Lin, Wei; Chapoval, Andrei; Strome, Scott E.

In: Cancer Immunology, Immunotherapy, Vol. 63, No. 9, 01.01.2014, p. 947-958.

Research output: Contribution to journalArticle

Sallin, Michelle A. ; Zhang, Xiaoyu ; So, Edward C. ; Burch, Erin ; Cai, Ling ; Lin, Wei ; Chapoval, Andrei ; Strome, Scott E. / The anti-lymphoma activities of anti-CD137 monoclonal antibodies are enhanced in FcγRIII-/- mice. In: Cancer Immunology, Immunotherapy. 2014 ; Vol. 63, No. 9. pp. 947-958.
@article{60d207d0e841430b873da72e63f82549,
title = "The anti-lymphoma activities of anti-CD137 monoclonal antibodies are enhanced in FcγRIII-/- mice",
abstract = "Agonistic monoclonal antibodies (mAbs) directed against the co-signaling molecule CD137 (4-1BB) elicit potent anti-tumor immunity in mice. This anti-tumor immunity has traditionally been thought to result from the ability of the Fab portion of anti-CD137 to function as an analog for CD137L. Although binding of CD137 by anti-CD137 mAbs has the potential to cross-link the Fc fragments, enabling Fc engagement of low to moderate affinity Fc gamma receptors (FcγR), the relative import of such Fc-FcγR interactions in mediating anti-CD137 associated anti-tumor immunity is unknown. We studied the ability of a rat anti-mouse CD137 mAb (2A) to mediate the anti-tumor response against the EL4E7 lymphoma in WT and FcγR-/- strains. 2A-treated FcRγ-/- mice had improved anti-tumor immunity against EL4E7, which could be completely recapitulated in FcγRIII -/- animals. These improved anti-tumor responses were associated with increased splenic CD8β T cell and dendritic cell (DC) populations. Furthermore, there was an increase in the number of DCs expressing high levels of the CD40, CD80, and CD86 molecules that are associated with more effective antigen presentation. Our results demonstrate an unexpected inhibitory role for FcγRIII in the anti-tumor function of anti-CD137 and underscore the need to consider antibody isotype when engineering therapeutic mAbs.",
keywords = "4-1BB, Cancer, CD137, Dendritic cell, Fcγ receptor, Monoclonal antibody",
author = "Sallin, {Michelle A.} and Xiaoyu Zhang and So, {Edward C.} and Erin Burch and Ling Cai and Wei Lin and Andrei Chapoval and Strome, {Scott E.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s00262-014-1567-2",
language = "English (US)",
volume = "63",
pages = "947--958",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "9",

}

TY - JOUR

T1 - The anti-lymphoma activities of anti-CD137 monoclonal antibodies are enhanced in FcγRIII-/- mice

AU - Sallin, Michelle A.

AU - Zhang, Xiaoyu

AU - So, Edward C.

AU - Burch, Erin

AU - Cai, Ling

AU - Lin, Wei

AU - Chapoval, Andrei

AU - Strome, Scott E.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Agonistic monoclonal antibodies (mAbs) directed against the co-signaling molecule CD137 (4-1BB) elicit potent anti-tumor immunity in mice. This anti-tumor immunity has traditionally been thought to result from the ability of the Fab portion of anti-CD137 to function as an analog for CD137L. Although binding of CD137 by anti-CD137 mAbs has the potential to cross-link the Fc fragments, enabling Fc engagement of low to moderate affinity Fc gamma receptors (FcγR), the relative import of such Fc-FcγR interactions in mediating anti-CD137 associated anti-tumor immunity is unknown. We studied the ability of a rat anti-mouse CD137 mAb (2A) to mediate the anti-tumor response against the EL4E7 lymphoma in WT and FcγR-/- strains. 2A-treated FcRγ-/- mice had improved anti-tumor immunity against EL4E7, which could be completely recapitulated in FcγRIII -/- animals. These improved anti-tumor responses were associated with increased splenic CD8β T cell and dendritic cell (DC) populations. Furthermore, there was an increase in the number of DCs expressing high levels of the CD40, CD80, and CD86 molecules that are associated with more effective antigen presentation. Our results demonstrate an unexpected inhibitory role for FcγRIII in the anti-tumor function of anti-CD137 and underscore the need to consider antibody isotype when engineering therapeutic mAbs.

AB - Agonistic monoclonal antibodies (mAbs) directed against the co-signaling molecule CD137 (4-1BB) elicit potent anti-tumor immunity in mice. This anti-tumor immunity has traditionally been thought to result from the ability of the Fab portion of anti-CD137 to function as an analog for CD137L. Although binding of CD137 by anti-CD137 mAbs has the potential to cross-link the Fc fragments, enabling Fc engagement of low to moderate affinity Fc gamma receptors (FcγR), the relative import of such Fc-FcγR interactions in mediating anti-CD137 associated anti-tumor immunity is unknown. We studied the ability of a rat anti-mouse CD137 mAb (2A) to mediate the anti-tumor response against the EL4E7 lymphoma in WT and FcγR-/- strains. 2A-treated FcRγ-/- mice had improved anti-tumor immunity against EL4E7, which could be completely recapitulated in FcγRIII -/- animals. These improved anti-tumor responses were associated with increased splenic CD8β T cell and dendritic cell (DC) populations. Furthermore, there was an increase in the number of DCs expressing high levels of the CD40, CD80, and CD86 molecules that are associated with more effective antigen presentation. Our results demonstrate an unexpected inhibitory role for FcγRIII in the anti-tumor function of anti-CD137 and underscore the need to consider antibody isotype when engineering therapeutic mAbs.

KW - 4-1BB

KW - Cancer

KW - CD137

KW - Dendritic cell

KW - Fcγ receptor

KW - Monoclonal antibody

UR - http://www.scopus.com/inward/record.url?scp=84906938452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906938452&partnerID=8YFLogxK

U2 - 10.1007/s00262-014-1567-2

DO - 10.1007/s00262-014-1567-2

M3 - Article

C2 - 24927849

AN - SCOPUS:84906938452

VL - 63

SP - 947

EP - 958

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 9

ER -